Janux Therapeutics/JANX

$40.20

166.22%
-
1D1W1MYTD1YMAX

About Janux Therapeutics

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is engaged in developing a pipeline of immunotherapies by applying its technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to treat patients suffering from cancer. Its initial focus is on developing a class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. It is developing a pipeline with programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Its pipeline includes PSMA-TRACTr, EGFR-TRACTr, and TROP2-TRACTr. PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. Its EGFR-TRACTr is designed to target EGFR. TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target. Its TRACIr program targets PD-L1xCD28.

Ticker

JANX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

David Campbell

Employees

60

Headquarters

San diego, United States

JANX Metrics

BasicAdvanced
$724.38M
Market cap
-
P/E ratio
-$1.48
EPS
-
Beta
-
Dividend rate

What the Analysts think about JANX

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
34.7% downside
High $35.00
Low $21.00
$40.20
Current price
$26.25
Average price target

JANX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-460% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$2.5M
150%
Net income
$-11.5M
-34.29%
Profit margin
-460%
-73.71%

JANX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 46.81%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.39
-$0.42
-$0.42
-$0.25
-
Expected
-$0.49
-$0.49
-$0.52
-$0.47
-$0.41
Surprise
-19.84%
-14.59%
-18.84%
-46.81%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Janux Therapeutics stock

Buy or sell Janux Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing